SI9720048B - Derivati piridazino /4,5-b/-kinolin 5-oksida, njihova priprava in njihova uporaba kot antagonisti glicina - Google Patents
Derivati piridazino /4,5-b/-kinolin 5-oksida, njihova priprava in njihova uporaba kot antagonisti glicina Download PDFInfo
- Publication number
- SI9720048B SI9720048B SI9720048A SI9720048A SI9720048B SI 9720048 B SI9720048 B SI 9720048B SI 9720048 A SI9720048 A SI 9720048A SI 9720048 A SI9720048 A SI 9720048A SI 9720048 B SI9720048 B SI 9720048B
- Authority
- SI
- Slovenia
- Prior art keywords
- quinoline
- oxo
- hydroxy
- oxide
- dihydropyridazino
- Prior art date
Links
- 229940127337 Glycine Antagonists Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 3
- 208000025966 Neurological disease Diseases 0.000 claims abstract 3
- 241000551547 Dione <red algae> Species 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- -1 methylenedioxy Chemical group 0.000 claims abstract 2
- 229960001231 choline Drugs 0.000 claims 22
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- ABLAXEXWCSKSLS-UHFFFAOYSA-N ClC1=C(Br)C=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 Chemical compound ClC1=C(Br)C=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 ABLAXEXWCSKSLS-UHFFFAOYSA-N 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- HIGOKJCMNNRPHC-UHFFFAOYSA-N BrC1=CC=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 Chemical compound BrC1=CC=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 HIGOKJCMNNRPHC-UHFFFAOYSA-N 0.000 claims 5
- CZIVVSZSZNUYHA-UHFFFAOYSA-N C1=CC=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 Chemical compound C1=CC=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 CZIVVSZSZNUYHA-UHFFFAOYSA-N 0.000 claims 5
- BUWUYXIYKSUCPC-UHFFFAOYSA-N BrC1=C(Cl)C=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 Chemical compound BrC1=C(Cl)C=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 BUWUYXIYKSUCPC-UHFFFAOYSA-N 0.000 claims 4
- JDSMEWAYIYQMLN-UHFFFAOYSA-N FC1=CC=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 Chemical compound FC1=CC=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 JDSMEWAYIYQMLN-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- WYLPPZNVGFIEHU-UHFFFAOYSA-N O=C1NNC(=O)C2=C1[N+]([O-])=C1C=CC(Cl)=CC1=C2 Chemical compound O=C1NNC(=O)C2=C1[N+]([O-])=C1C=CC(Cl)=CC1=C2 WYLPPZNVGFIEHU-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000003248 quinolines Chemical group 0.000 claims 4
- 239000004381 Choline salt Substances 0.000 claims 3
- IEHWAAZUXFGVMD-UHFFFAOYSA-N ClC1=C(Cl)C=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 Chemical compound ClC1=C(Cl)C=C2[N+]([O-])=C3C(O)=NNC(=O)C3=CC2=C1 IEHWAAZUXFGVMD-UHFFFAOYSA-N 0.000 claims 3
- 235000019417 choline salt Nutrition 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000005040 opiate dependence Diseases 0.000 claims 2
- NMXSPMUWIBLPJA-UHFFFAOYSA-N 2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione Chemical compound C1=CC=C2C=C3C(=O)NNC(=O)C3=NC2=C1 NMXSPMUWIBLPJA-UHFFFAOYSA-N 0.000 claims 1
- CJHJISDERTZDJM-UHFFFAOYSA-N 7,8-dichloro-2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione Chemical compound ClC1=C(Cl)C=C2N=C3C(O)=NNC(=O)C3=CC2=C1 CJHJISDERTZDJM-UHFFFAOYSA-N 0.000 claims 1
- FWAXESGOFYOTCO-UHFFFAOYSA-N 8-bromo-7-chloro-2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione Chemical compound BrC1=C(Cl)C=C2N=C3C(O)=NNC(=O)C3=CC2=C1 FWAXESGOFYOTCO-UHFFFAOYSA-N 0.000 claims 1
- GZKIZNLGYWADIV-UHFFFAOYSA-N 8-fluoro-2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione Chemical compound O=C1NNC(=O)C=2C1=CC1=CC(F)=CC=C1N=2 GZKIZNLGYWADIV-UHFFFAOYSA-N 0.000 claims 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000003492 excitotoxic effect Effects 0.000 abstract 1
- 231100000063 excitotoxicity Toxicity 0.000 abstract 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/686,346 US5776935A (en) | 1996-07-25 | 1996-07-25 | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission |
| PCT/EP1997/004057 WO1998004556A1 (en) | 1996-07-25 | 1997-07-25 | Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9720048A SI9720048A (sl) | 1999-12-31 |
| SI9720048B true SI9720048B (sl) | 2002-02-28 |
Family
ID=24755940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9720048A SI9720048B (sl) | 1996-07-25 | 1997-07-25 | Derivati piridazino /4,5-b/-kinolin 5-oksida, njihova priprava in njihova uporaba kot antagonisti glicina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5776935A (cs) |
| EP (1) | EP0931081B1 (cs) |
| JP (1) | JP3595342B2 (cs) |
| KR (1) | KR100598206B1 (cs) |
| CN (1) | CN1093860C (cs) |
| AR (1) | AR004158A1 (cs) |
| AT (1) | ATE224894T1 (cs) |
| AU (1) | AU719993B2 (cs) |
| BR (1) | BR9710569A (cs) |
| CA (1) | CA2261923C (cs) |
| CZ (1) | CZ289293B6 (cs) |
| DE (1) | DE69715893T2 (cs) |
| DK (1) | DK0931081T3 (cs) |
| EA (1) | EA001711B1 (cs) |
| ES (1) | ES2180041T3 (cs) |
| FI (1) | FI112946B (cs) |
| GE (1) | GEP20022801B (cs) |
| HU (1) | HU223780B1 (cs) |
| IL (1) | IL128225A (cs) |
| LT (1) | LT4591B (cs) |
| LV (1) | LV12260B (cs) |
| NO (1) | NO310820B1 (cs) |
| PL (1) | PL189572B1 (cs) |
| PT (1) | PT931081E (cs) |
| SI (1) | SI9720048B (cs) |
| SK (1) | SK283536B6 (cs) |
| TW (1) | TW402605B (cs) |
| UA (1) | UA63911C2 (cs) |
| WO (1) | WO1998004556A1 (cs) |
| ZA (1) | ZA976612B (cs) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030176435A1 (en) * | 2002-12-17 | 2003-09-18 | Brown Dean Gordon | Compounds and methods for the treatment of pain |
| US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| CA2457011C (en) * | 2001-08-20 | 2012-04-24 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| EP1298581A1 (fr) * | 2001-09-27 | 2003-04-02 | C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa | Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal |
| US20050069596A1 (en) * | 2001-10-03 | 2005-03-31 | Gow Robert T. | Compositions and methods comprising kava and anti-anxiety compounds |
| US7001620B2 (en) | 2001-10-03 | 2006-02-21 | Herbal Science, Llc | Kavalactone product |
| US7037524B2 (en) * | 2001-10-03 | 2006-05-02 | Herbalscience, Llc | Oral delivery of a botanical |
| US7029707B2 (en) * | 2001-10-03 | 2006-04-18 | Herbalscience, Llc | Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| US7291352B2 (en) | 2001-10-03 | 2007-11-06 | Herbalscience Llc | Methods and compositions for oral delivery of Areca and mate' or theobromine |
| US7105185B2 (en) | 2001-10-03 | 2006-09-12 | Herbalscience, Llc | Kavalactone profile |
| US20050037025A1 (en) * | 2002-10-03 | 2005-02-17 | Gow Robert T. | Methods and compositions comprising kava and mate' or theobromine |
| US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| RU2266118C2 (ru) * | 2003-10-21 | 2005-12-20 | Общество с ограниченной ответственностью "Абидофарма" | Мазь для лечения аутоиммунных заболеваний |
| RU2266119C2 (ru) * | 2003-10-21 | 2005-12-20 | Общество с ограниченной ответственностью "Абидофарма" | Препарат для ингаляций при лечении туберкулеза |
| CN1917892A (zh) * | 2003-10-24 | 2007-02-21 | 草本制药科学有限责任公司 | 包含冬青的方法和组合物 |
| US7294353B2 (en) * | 2003-10-24 | 2007-11-13 | Herbalscience, Llc | Methods and compositions comprising ilex |
| AU2006258217A1 (en) * | 2005-04-08 | 2006-12-21 | Abbott Laboratories | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts |
| WO2009038752A2 (en) * | 2007-09-20 | 2009-03-26 | Cortex Pharmaceuticals, Inc. | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
| EP2264035A1 (en) * | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| CA3067162A1 (en) | 2017-06-12 | 2018-12-20 | Glytech Llc. | Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists |
| USD895157S1 (en) | 2018-03-06 | 2020-09-01 | IsoTruss Indsutries LLC | Longitudinal beam |
| CN109912503B (zh) * | 2019-04-01 | 2022-04-08 | 江南大学 | 一种2,3-二酰基喹啉类化合物的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9208511D0 (en) * | 1991-05-09 | 1992-06-03 | Ici Plc | Compounds |
| US5597922A (en) * | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
-
1996
- 1996-07-25 US US08/686,346 patent/US5776935A/en not_active Expired - Fee Related
-
1997
- 1997-07-23 TW TW086110479A patent/TW402605B/zh not_active IP Right Cessation
- 1997-07-24 ZA ZA9706612A patent/ZA976612B/xx unknown
- 1997-07-25 EP EP97918944A patent/EP0931081B1/en not_active Expired - Lifetime
- 1997-07-25 HU HU9903104A patent/HU223780B1/hu active IP Right Grant
- 1997-07-25 SI SI9720048A patent/SI9720048B/sl not_active IP Right Cessation
- 1997-07-25 JP JP50849998A patent/JP3595342B2/ja not_active Expired - Fee Related
- 1997-07-25 AR ARP970103380A patent/AR004158A1/es active IP Right Grant
- 1997-07-25 AU AU42969/97A patent/AU719993B2/en not_active Ceased
- 1997-07-25 AT AT97918944T patent/ATE224894T1/de not_active IP Right Cessation
- 1997-07-25 CA CA002261923A patent/CA2261923C/en not_active Expired - Fee Related
- 1997-07-25 WO PCT/EP1997/004057 patent/WO1998004556A1/en active IP Right Grant
- 1997-07-25 IL IL12822597A patent/IL128225A/xx not_active IP Right Cessation
- 1997-07-25 EA EA199900161A patent/EA001711B1/ru not_active IP Right Cessation
- 1997-07-25 DE DE69715893T patent/DE69715893T2/de not_active Expired - Fee Related
- 1997-07-25 UA UA99021084A patent/UA63911C2/uk unknown
- 1997-07-25 GE GEAP19974684A patent/GEP20022801B/en unknown
- 1997-07-25 DK DK97918944T patent/DK0931081T3/da active
- 1997-07-25 SK SK103-99A patent/SK283536B6/sk unknown
- 1997-07-25 PT PT97918944T patent/PT931081E/pt unknown
- 1997-07-25 KR KR1019997000627A patent/KR100598206B1/ko not_active Expired - Fee Related
- 1997-07-25 ES ES97918944T patent/ES2180041T3/es not_active Expired - Lifetime
- 1997-07-25 CZ CZ1999201A patent/CZ289293B6/cs unknown
- 1997-07-25 BR BR9710569A patent/BR9710569A/pt not_active Application Discontinuation
- 1997-07-25 CN CN97197534A patent/CN1093860C/zh not_active Expired - Fee Related
- 1997-07-25 PL PL97331323A patent/PL189572B1/pl not_active IP Right Cessation
-
1999
- 1999-01-22 LV LVP-99-14A patent/LV12260B/en unknown
- 1999-01-22 NO NO19990306A patent/NO310820B1/no unknown
- 1999-01-25 FI FI990134A patent/FI112946B/fi active
- 1999-01-25 LT LT99-007A patent/LT4591B/lt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9720048B (sl) | Derivati piridazino /4,5-b/-kinolin 5-oksida, njihova priprava in njihova uporaba kot antagonisti glicina | |
| ES2198196B2 (es) | Composiciones topicas que comprenden un analgesico opioide y un antagonista de nmda. | |
| DK1119567T3 (da) | Quinazolinderivater | |
| IL128994A0 (en) | Quinoline derivatives inhibiting the effect of growth factors such as vegf | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| CA2263319A1 (en) | Quinazoline derivatives and pharmaceutical compositions containing them | |
| EE200200245A (et) | Farmatseutiline kompositsioon, mis sisaldab tolterodiini ja selle kasutamine | |
| NO20065078L (no) | Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister. | |
| BR9909253A (pt) | Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico | |
| Wachtel | Neurotropic effects of the optical isomers of the selective adenosine cyclic 3′, 5′‐monophosphate phosphodiesterase inhibitor rolipram in rats in‐vivo | |
| NO20041059L (no) | Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| WO2002000166A3 (en) | New compounds useful as antibacterial agents | |
| MY108482A (en) | Compounds. | |
| CA2535637C (en) | Quinolone antibiotics for the systemic treatment of bacterial infections of the oral cavity | |
| WO2001085095A3 (en) | Chiral fluoroquinolizinone arginine salt forms | |
| ITMI950379A1 (it) | Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico | |
| IE780217L (en) | 1,3,5-triazine-2,6-dione derivatives | |
| DE69927997D1 (de) | Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung | |
| BRPI0412453A (pt) | uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo | |
| ES2311812T3 (es) | Uso de acetales/cetales ciclicos para mejorar la penetracion de principios activos en celulas y organos. | |
| CA2797347A1 (en) | Methods and compositions for treating dry eye | |
| SI9300150B (sl) | Kristalne oblike endo-2,3-dihidro-N-(8-metil-8-azabicilo/3.2.1./okt-3-il)-2-okso-1H- benzimidazol-1-karboksamid hidroklorid monohidrata in endo-3-etil-2,3-dihidro-N-(8-metil-8-azabiciklo/3.2.1/okt-3-il)-2-okso- 1H-benzimidazol-1-karboksamid hidroklorid monohidrata | |
| RU2021113497A (ru) | Суспензионные композиции высоконцентрированных дисперсий | |
| ES2558085T3 (es) | Dentífrico libre de fluoruro y libre de surfactantes aniónicos que tiene una alta eficacia micro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| KO00 | Lapse of patent |
Effective date: 20090325 |